The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial release generated massive profits, the lapse of its exclusive rights opened the avenue to cheaper https://crossbookmark.com/story21505802/sildenafil-and-the-pharmaceutical-industry-a-volatile-bet